Wall Street Zen Upgrades Zimmer Biomet (NYSE:ZBH) to Buy

Posted by George Bondi on Jul 27th, 2026

Zimmer Biomet (NYSE:ZBH – Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Saturday.

A number of other analysts have also commented on ZBH. BMO Capital Markets started coverage on shares of Zimmer Biomet in a research note on Wednesday, July 8th. They set a “market perform” rating and a $95.00 price objective for the company. Weiss Ratings downgraded shares of Zimmer Biomet from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, July 20th. Barclays cut their price target on shares of Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating on the stock in a report on Wednesday, April 29th. Robert W. Baird set a $92.00 price target on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Finally, Citigroup decreased their price objective on shares of Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating for the company in a research note on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have issued a Hold rating and four have given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $100.70.

View Our Latest Stock Report on Zimmer Biomet

Zimmer Biomet Stock Performance

Shares of NYSE ZBH opened at $91.35 on Friday. The stock’s fifty day simple moving average is $87.90 and its 200 day simple moving average is $89.79. The stock has a market capitalization of $17.67 billion, a price-to-earnings ratio of 23.73, a PEG ratio of 2.69 and a beta of 0.46. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50. Zimmer Biomet has a 52-week low of $79.12 and a 52-week high of $108.29.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last announced its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, beating the consensus estimate of $1.86 by $0.23. The business had revenue of $2.09 billion during the quarter, compared to the consensus estimate of $2.07 billion. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.Zimmer Biomet’s revenue was up 9.3% compared to the same quarter last year. During the same period in the prior year, the business posted $1.81 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, sell-side analysts forecast that Zimmer Biomet will post 8.48 earnings per share for the current fiscal year.

Insider Buying and Selling at Zimmer Biomet

In other news, insider Sang Yi sold 5,000 shares of the stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the sale, the insider directly owned 27,251 shares of the company’s stock, valued at $2,252,022.64. This represents a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.28% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ZBH. Tema ETFs LLC boosted its stake in shares of Zimmer Biomet by 39.8% during the 2nd quarter. Tema ETFs LLC now owns 4,194 shares of the medical equipment provider’s stock valued at $361,000 after buying an additional 1,194 shares during the period. Kentucky Trust Co increased its stake in shares of Zimmer Biomet by 285.0% in the second quarter. Kentucky Trust Co now owns 770 shares of the medical equipment provider’s stock worth $66,000 after acquiring an additional 570 shares during the last quarter. Handelsbanken Fonder AB increased its stake in shares of Zimmer Biomet by 22.7% in the second quarter. Handelsbanken Fonder AB now owns 152,064 shares of the medical equipment provider’s stock worth $13,091,000 after acquiring an additional 28,130 shares during the last quarter. Valeo Financial Advisors LLC raised its holdings in shares of Zimmer Biomet by 1.6% during the second quarter. Valeo Financial Advisors LLC now owns 11,176 shares of the medical equipment provider’s stock worth $962,000 after acquiring an additional 175 shares in the last quarter. Finally, Wilsey Asset Management Inc. boosted its position in Zimmer Biomet by 4.7% during the second quarter. Wilsey Asset Management Inc. now owns 421,867 shares of the medical equipment provider’s stock valued at $36,318,000 after purchasing an additional 18,883 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

(Get Free Report)

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.